Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Successful febuxostat desensitization in a patient with febuxostat hypersensitivity: A Malaysian experience.

Sulaiman N, Othman AZ, Shahril NS, Abdul Rashid AM, Md Noh MSF.

SAGE Open Med Case Rep. 2017 Dec 17;5:2050313X17749080. doi: 10.1177/2050313X17749080. eCollection 2017.

2.

Tumor Lysis Syndrome in Patients with Hematological Malignancies.

Belay Y, Yirdaw K, Enawgaw B.

J Oncol. 2017;2017:9684909. doi: 10.1155/2017/9684909. Epub 2017 Nov 2. Review.

3.

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.

Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases.

Chin Med J (Engl). 2017 Oct 20;130(20):2473-2488. doi: 10.4103/0366-6999.216416. No abstract available.

4.

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.

Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L.

Arthritis Rheumatol. 2017 Dec;69(12):2386-2395. doi: 10.1002/art.40233.

5.

Gout: An old disease in new perspective - A review.

Ragab G, Elshahaly M, Bardin T.

J Adv Res. 2017 Sep;8(5):495-511. doi: 10.1016/j.jare.2017.04.008. Epub 2017 May 10. Review.

6.

Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease.

Signorini L, Granata S, Lupo A, Zaza G.

Int J Mol Sci. 2017 Jul 10;18(7). pii: E1481. doi: 10.3390/ijms18071481. Review.

7.

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.

Arthritis Rheumatol. 2017 Sep;69(9):1903-1913. doi: 10.1002/art.40159. Epub 2017 Aug 4.

8.

Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.

Yamaguchi A, Harada M, Yamada Y, Hashimoto K, Kamijo Y.

BMC Nephrol. 2017 May 18;18(1):162. doi: 10.1186/s12882-017-0572-z.

9.

Treatment approaches and adherence to urate-lowering therapy for patients with gout.

Aung T, Myung G, FitzGerald JD.

Patient Prefer Adherence. 2017 Apr 19;11:795-800. doi: 10.2147/PPA.S97927. eCollection 2017. Review.

10.

Management of Gout and Hyperuricemia in CKD.

Vargas-Santos AB, Neogi T.

Am J Kidney Dis. 2017 Sep;70(3):422-439. doi: 10.1053/j.ajkd.2017.01.055. Epub 2017 Apr 26.

PMID:
28456346
11.

Treatment Options for Gout.

Engel B, Just J, Bleckwenn M, Weckbecker K.

Dtsch Arztebl Int. 2017 Mar 31;114(13):215-222. doi: 10.3238/arztebl.2017.0215.

12.

Risk of Febuxostat-Associated Myopathy in Patients with CKD.

Liu CT, Chen CY, Hsu CY, Huang PH, Lin FY, Chen JW, Lin SJ.

Clin J Am Soc Nephrol. 2017 May 8;12(5):744-750. doi: 10.2215/CJN.08280816. Epub 2017 Mar 16.

PMID:
28302902
13.

Use of febuxostat in the management of gout in the United Kingdom.

Waller A, Jordan KM.

Ther Adv Musculoskelet Dis. 2017 Feb;9(2):55-64. doi: 10.1177/1759720X16682010. Epub 2016 Dec 28. Review.

14.

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.

Bove M, Cicero AF, Veronesi M, Borghi C.

Vasc Health Risk Manag. 2017 Feb 8;13:23-28. doi: 10.2147/VHRM.S115080. eCollection 2017. Review.

15.

The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.

Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK.

Semin Arthritis Rheum. 2017 Apr;46(5):594-600. doi: 10.1016/j.semarthrit.2016.10.009. Epub 2016 Nov 1.

PMID:
27916277
16.

Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study.

Ito H, Antoku S, Abe M, Omoto T, Shinozaki M, Nishio S, Mifune M, Togane M, Nakata M, Yamashita T.

Intern Med. 2016;55(22):3247-3256. Epub 2016 Nov 15.

17.

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A.

Ann Rheum Dis. 2017 May;76(5):811-820. doi: 10.1136/annrheumdis-2016-209213. Epub 2016 Nov 7.

18.

An old disease with new insights: Update on diagnosis and treatment of gout.

Bitik B, Öztürk MA.

Eur J Rheumatol. 2014 Jun;1(2):72-77. Epub 2014 Jun 1. Review.

19.

Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.

Li S, Yang H, Guo Y, Wei F, Yang X, Li D, Li M, Xu W, Li W, Sun L, Gao Y, Wang Y.

Sci Rep. 2016 Sep 8;6:33082. doi: 10.1038/srep33082.

20.

Poorly controlled gout: who is doing poorly?

Chia FL.

Singapore Med J. 2016 Aug;57(8):412-4. doi: 10.11622/smedj.2016129.

Supplemental Content

Support Center